Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11332590 | 1.00 | LMNA (0.56) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL4418542 | 1.00 | LMNA (0.56) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL2583348 | 1.00 | LMNA (0.56) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL5583939 | 0.88 | DNMT1 (0.43) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL11319563 | 0.88 | LMNA (0.55) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL11319557 | 0.88 | LMNA (0.55) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL1140052 | 0.88 | LMNA (0.55) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL1527270 | 0.88 | LMNA (0.55) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL9856409 | 0.87 | LMNA (0.62) | LMNAMTORALDH1A1DNMT1THRB | |
| SCHEMBL156036 | 0.87 | LMNA (0.62) | LMNAMTORALDH1A1DNMT1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520531-A | Product and composition | SILENCE THERAPEUTICS GMBH | 2019-11-29 | — | — | CN | disclosed |
| CN-110337429-A | Ionizable cation lipid for RNA delivery | 阿克丘勒斯治疗公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-110325511-A | Ionizable cationic lipids for RNA delivery | 阿克丘勒斯治疗公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-109640632-A | For controlling plant and the method for fungal plant pathogen | 马尼托巴大学 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562188-A | Nucleic acids linked to trivalent saccharide conjugates | 赛伦斯治疗有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109477109-A | Target the oligonucleotide analogs of people LMNA | 萨勒普塔医疗公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-108779163-A | Dual control for therapeutic cell activation or elimination | 贝里坤制药股份有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-108136040-A | For the multiple ligand reagent of drug delivery | 阿克丘勒斯治疗公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107207428-A | Ionizable cation lipid for RNA delivery | 阿克丘勒斯治疗公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-106460053-A | MIRNA expression profiling in thyroid tumor classification | 罗塞塔金诺米克斯有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-101426912-A | Chemically modified short interfering nucleic acid molecules that mediate RNA interference | RIBOZYME PHARM INC (US) | 2009-05-06 | — | — | CN | disclosed |
| CN-101355970-A | Peptide-DICER substrate RNA conjugates as delivery vehicles for SIRNA | NASTECH PHARM CO (US) | 2009-01-28 | — | — | CN | disclosed |
| US-20090018097-A1 | MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES | MDRNA, INC (US) | 2009-01-15 | — | — | US | disclosed |
| CN-101208438-A | Methods of treating inflammatory diseases using double-stranded ribonucleic acids | NASTECH PHARM CO (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-101137662-A | Deprotection and purification of oligonucleotides and derivatives thereof | SIRNA THERAPEUTICS INC (US) | 2008-03-05 | — | — | CN | disclosed |
| WO-2007030167-A1 | MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-5859234-A | 2'-O-methyl cytidine monomer useful in oligonucleotide synthesis | GENTA, INCORPORATED (US) | 1999-01-12 | — | — | US | disclosed |
| US-5652359-A | Oligonucleotides containing n-methyl thiolated bases having antiviral activity | EPOCH PHARMACEUTICALS, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5606049-A | Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis | GENTA INCORPORATED (US) | 1997-02-25 | — | — | US | disclosed |
| US-4267171-A | C-5 Substituted cytosine nucleosides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018097-A1 | MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES | ADAR, EIF2AK2, RNASEH1 | LMNA 2279/4885MTOR 3310/4885ALDH1A1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.